Hodgkin lymphoma is a special type of lymphoma in which tumor cells frequently undergo multiple genetic lesions that are associated with accompanying pathway abnormalities. These pathway abnormalities are dominated by active signaling pathways, such as the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway and the NFκB (nuclear factor kappa-B) pathway, which usually result in hyperactive survival signaling. Targeted therapies often play an important role in hematologic malignancies, such as CAR-T therapy (chimeric antigen receptor T-cell immunotherapy) targeting CD19 and CD22 in diffuse large B-cell lymphoma, while in Hodgkin lymphoma, the main targets of targeted therapies are CD30 molecules and PD1 molecules. Drugs targeting other molecules are also under investigation. This review summarizes the actionable genetic lesions, current treatment options, clinical trials for Hodgkin lymphoma and the potential value of those genetic lesions in clinical applications.
Keyphrases
- hodgkin lymphoma
- nuclear factor
- diffuse large b cell lymphoma
- toll like receptor
- genome wide
- clinical trial
- signaling pathway
- copy number
- epstein barr virus
- cancer therapy
- inflammatory response
- dna methylation
- transcription factor
- stem cells
- epithelial mesenchymal transition
- cell proliferation
- risk assessment
- protein kinase
- smoking cessation